Bank of America
KZR

Bank of America’s Kezar Life Sciences KZR Stock Holding History

Bank of America’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122
Closed -$768 – 6363
2025
Q4 		$768 Buy
122
+1
+0.8% +$6 ﹤0.01% 6500
2025
Q3 		$472 Sell
121
-59
-33% -$242 ﹤0.01% 7597
2025
Q2 		$824 Buy
180
+8
+5% +$34 ﹤0.01% 7569
2025
Q1 		$839 Buy
172
+2
+1% +$12 ﹤0.01% 7450
2024
Q4 		$1.14K Hold
170
– – ﹤0.01% 7266
2024
Q3 		$1.32K Sell
170
-10,369
-98% -$62.5K ﹤0.01% 7194
2024
Q2 		$63.2K Buy
10,539
+7,214
+217% +$54.8K ﹤0.01% 6440
2024
Q1 		$30K Sell
3,325
-5,599
-63% -$51K ﹤0.01% 6665
2023
Q4 		$84.5K Buy
8,924
+2,482
+39% +$21.8K ﹤0.01% 6440
2023
Q3 		$76.7K Buy
6,442
+1,362
+27% +$24.1K ﹤0.01% 6360
2023
Q2 		$124K Sell
5,080
-26,695
-84% -$695K ﹤0.01% 6106
2023
Q1 		$995K Sell
31,775
-2,758
-8% -$160K ﹤0.01% 4903
2022
Q4 		$2.43M Buy
34,533
+11,350
+49% +$842K ﹤0.01% 4081
2022
Q3 		$2M Buy
23,183
+21,935
+1,758% +$2.13M ﹤0.01% 4278
2022
Q2 		$103K Sell
1,248
-3,847
-76% -$339K ﹤0.01% 6446
2022
Q1 		$847K Sell
5,095
-9,721
-66% -$1.4M ﹤0.01% 5407
2021
Q4 		$2.48M Buy
14,816
+9,204
+164% +$1.04M ﹤0.01% 4346
2021
Q3 		$484K Buy
5,612
+3,365
+150% +$223K ﹤0.01% 5669
2021
Q2 		$122K Sell
2,247
-978
-30% -$55.5K ﹤0.01% 6408
2021
Q1 		$192K Buy
3,225
+1,609
+100% +$94K ﹤0.01% 6074
2020
Q4 		$84K Sell
1,616
-273
-14% -$15.2K ﹤0.01% 6077
2020
Q3 		$92K Sell
1,889
-779
-29% -$37.3K ﹤0.01% 5750
2020
Q2 		$138K Buy
2,668
+857
+47% +$43.2K ﹤0.01% 5496
2020
Q1 		$79K Sell
1,811
-1,175
-39% -$47.8K ﹤0.01% 5646
2019
Q4 		$120K Buy
2,986
+618
+26% +$19K ﹤0.01% 5914
2019
Q3 		$78K Buy
2,368
+791
+50% +$38.2K ﹤0.01% 6158
2019
Q2 		$122K Buy
1,577
+354
+29% +$55K ﹤0.01% 5902
2019
Q1 		$217K Buy
1,223
+933
+322% +$184K ﹤0.01% 5487
2018
Q4 		$67K Buy
290
+186
+179% +$45.5K ﹤0.01% 6098
2018
Q3 		$23K Buy
+104
New +$18.2K ﹤0.01% 6475

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Bank of America's KZR Position: Q1 2026 in Review

Bank of America sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 122 shares — an estimated $768 sold.

Bank of America first reported a position in KZR in Q3 2018 and held it in 30 quarters. The position peaked at $2.48M in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Bank of America reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 122 Kezar Life Sciences shares in Q1 2026, an estimated $768.
  • Bank of America first reported a position in Kezar Life Sciences in Q3 2018 and held it in 30 quarters.
  • Bank of America's Kezar Life Sciences position peaked at $2.48M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.